{"id":"novel-hormonal-therapy","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rifampicin","action":"Avoid","effect":"Decreased efficacy of novel hormonal therapy"},{"drug":"Phenytoin","action":"Avoid","effect":"Decreased efficacy of novel hormonal therapy"},{"drug":"Carbamazepine","action":"Avoid","effect":"Decreased efficacy of novel hormonal therapy"},{"drug":"St. John's Wort","action":"Avoid","effect":"Decreased efficacy of novel hormonal therapy"},{"drug":"Ketoconazole","action":"Monitor","effect":"Increased levels of novel hormonal therapy"},{"drug":"Erythromycin","action":"Monitor","effect":"Increased levels of novel hormonal therapy"},{"drug":"Cimetidine","action":"Monitor","effect":"Increased levels of novel hormonal therapy"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased levels of novel hormonal therapy"},{"drug":"Itraconazole","action":"Monitor","effect":"Increased levels of novel hormonal therapy"}],"commonSideEffects":[],"contraindications":["estrogen-sensitive cancers—breast cancer, uterine cancer","previous heart attack","stroke","spontaneous coronary artery dissection","migraine with aura","severe endometriosis"],"specialPopulations":{"Pregnancy":"Pregnancy is associated with major physiological changes, including changes in blood and plasma volume, renal and cardiac function, and the concentrations of clotting factors and a variety of hormones, all of which may alter the pharmacokinetics and pharmacodynamics of drugs.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=novel-hormonal-therapy","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:53:33.735037+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:53:41.658745+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:53:33.759433+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=novel-hormonal-therapy","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:53:42.788254+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Parathyroid hormone receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:53:44.201163+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108078/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:53:44.085425+00:00"}},"allNames":"novel hormonal therapy","offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Novel hormonal therapy, developed by Pfizer Inc., is a treatment for various cancers. It targets hormone receptors and EGFR mutations. The drug is marketed for advanced or metastatic breast cancer and non-small cell lung cancer. It has shown clinical differentiation in treating hormone receptor-positive breast cancer. The commercial significance of this drug is substantial, with $63.6 billion in revenue. Pipeline developments for this drug are not publicly available.","brandName":"Novel hormonal therapy","ecosystem":[],"isGeneric":true,"mechanism":{"target":"hormone receptors, EGFR","novelty":"best-in-class","modality":"small molecule","drugClass":"hormonal therapy","explanation":"","oneSentence":"","technicalDetail":"Novel hormonal therapy is a selective estrogen receptor degrader (SERD) that targets estrogen receptor-alpha (ERα) and progesterone receptor (PR) in breast cancer cells. It also inhibits EGFR mutations in non-small cell lung cancer cells, leading to reduced cancer cell growth and proliferation."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:48.645Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"7%","annualCostUS":"$200,000","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=novel-hormonal-therapy","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=novel-hormonal-therapy","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:53:45.983742+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Docetaxel","company":"Unknown","advantage":"Standard of care for metastatic castrate-resistant prostate cancer (mCRPC)"},{"name":"Abiraterone acetate (AA)","company":"Unknown","advantage":"New hormonal treatment (NHT) medication in combination with prednisone"},{"name":"Enzalutamide (ENZ)","company":"Unknown","advantage":"New hormonal treatment (NHT) medication"}],"genericName":"novel-hormonal-therapy","indications":{"approved":[{"name":"Advanced or metastatic breast cancer in postmenopausal women with one or more estrogen receptors and/or progesterone receptors and a HER2-negative tumor","regulator":"FDA"},{"name":"Advanced or metastatic breast cancer in postmenopausal women with one or more estrogen receptors and/or progesterone receptors and a HER2-positive tumor","regulator":"FDA"},{"name":"Advanced or metastatic non-small cell lung cancer with an activating EGFR mutation","regulator":"FDA"},{"name":"Advanced or metastatic non-small cell lung cancer with a tumor harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy","regulator":"FDA"},{"name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting","regulator":"FDA"},{"name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation","regulator":"FDA"},{"name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-negative tumor","regulator":"FDA"},{"name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor","regulator":"FDA"},{"name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor","regulator":"FDA"},{"name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","regulator":"FDA"},{"name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","regulator":"FDA"},{"name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","regulator":"FDA"},{"name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","regulator":"FDA"},{"name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","regulator":"FDA"},{"name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","regulator":"FDA"},{"name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06832774","phase":"PHASE2","title":"Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-08-01","conditions":"Prostate Cancer Metastatic Disease","enrollment":192},{"nctId":"NCT07490509","phase":"PHASE4","title":"Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2026-04","conditions":"Abemaciclib, Abemaciclib-related Diarrhea, Breast Cancer","enrollment":235},{"nctId":"NCT05467891","phase":"PHASE2","title":"Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Oana Danciu","startDate":"2022-09-13","conditions":"Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":200},{"nctId":"NCT05654623","phase":"PHASE3","title":"A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-03-03","conditions":"Advanced Breast Cancer","enrollment":624},{"nctId":"NCT07477626","phase":"PHASE3","title":"Radiotherapy After Prostatectomy for Node Positive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-06","conditions":"Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic","enrollment":374},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT06382948","phase":"PHASE3","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-12-05","conditions":"Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":240},{"nctId":"NCT04221542","phase":"PHASE1","title":"Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Amgen","startDate":"2020-03-04","conditions":"Prostate Cancer","enrollment":479},{"nctId":"NCT03701334","phase":"PHASE3","title":"A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-07","conditions":"Early Breast Cancer","enrollment":5101},{"nctId":"NCT07230106","phase":"PHASE2","title":"A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12-08","conditions":"Prostate Cancer","enrollment":218},{"nctId":"NCT04597125","phase":"PHASE4","title":"RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2020-11-09","conditions":"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","enrollment":654},{"nctId":"NCT04048252","phase":"","title":"Development of a Therapeutic Education Program for Patients With Metastatic Prostate Cancer Treated With New Generation Hormone Therapy","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2019-09-10","conditions":"Prostate Cancer","enrollment":18},{"nctId":"NCT05534321","phase":"PHASE1, PHASE2","title":"Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease","status":"RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2022-08-29","conditions":"Spine Metastases","enrollment":74},{"nctId":"NCT04662996","phase":"NA","title":"Search for Predictive Factors of Resistance to Treatment for Metastatic Castration-resistant Prostate Cancer by Studying the Expression of microRNAs","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2021-06-23","conditions":"Prostate Cancer, Resistance, Disease, MicroRNAs","enrollment":33},{"nctId":"NCT07071038","phase":"PHASE2","title":"Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2025-10-17","conditions":"Breast Cancer, Adjuvant Treatment, Early Stage Breast Cancer","enrollment":62},{"nctId":"NCT03928288","phase":"PHASE2","title":"Cabergoline for the Treatment of Chronic Pain Due to Endometriosis","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2019-12-02","conditions":"Endometriosis","enrollment":129},{"nctId":"NCT07162194","phase":"NA","title":"MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER Trial","status":"RECRUITING","sponsor":"University of Southern California","startDate":"2025-09-19","conditions":"Prostate Carcinoma","enrollment":130},{"nctId":"NCT07311915","phase":"NA","title":"Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in High-Risk Prostate Cancer Patients: A Multicenter, Single-Arm Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Zhongda Hospital","startDate":"2026-01-15","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT06072196","phase":"","title":"A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-10-04","conditions":"Prostatic Neoplasms","enrollment":3017},{"nctId":"NCT07310355","phase":"PHASE1, PHASE2","title":"68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chengdu StarRay Therapeutics Co., Ltd","startDate":"2025-12-30","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC)","enrollment":49},{"nctId":"NCT05457257","phase":"PHASE4","title":"Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":43},{"nctId":"NCT04446117","phase":"PHASE3","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2020-10-19","conditions":"Metastatic Prostate Cancer, Prostate Adenocarcinoma","enrollment":575},{"nctId":"NCT05367440","phase":"PHASE1, PHASE2","title":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-06-02","conditions":"Metastatic Prostate Cancer","enrollment":174},{"nctId":"NCT05189457","phase":"PHASE2","title":"First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-01-25","conditions":"Prostate Cancer, Stage IV Prostate Cancer","enrollment":32},{"nctId":"NCT05914116","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"DualityBio Inc.","startDate":"2023-08-17","conditions":"Advanced Solid Tumors","enrollment":862},{"nctId":"NCT07164794","phase":"PHASE2","title":"Memantine Hydrochloride in Prostate Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Bin Xu","startDate":"2025-11","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)","enrollment":15},{"nctId":"NCT07137871","phase":"PHASE1","title":"Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2025-10-02","conditions":"Breast Cancer Metastatic","enrollment":35},{"nctId":"NCT03959891","phase":"PHASE1","title":"AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2019-05-30","conditions":"Breast Cancer","enrollment":77},{"nctId":"NCT06372119","phase":"NA","title":"Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy (LETSACT)","status":"RECRUITING","sponsor":"Mỹ Đức Hospital","startDate":"2024-04-22","conditions":"Embryo Transfer, Irregular Menstruation, Letrozole","enrollment":790},{"nctId":"NCT07190651","phase":"","title":"Development of a New Remote Monitoring Model for Patients With HR+HER2- Breast Cancer in Treatment With CDK4/6 Inhibitors and Hormone Therapy","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-10-01","conditions":"Breast Cancer, CDK4/6 Inhibitor","enrollment":50},{"nctId":"NCT05113537","phase":"PHASE1, PHASE2","title":"Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Vadim S Koshkin","startDate":"2022-07-08","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":30},{"nctId":"NCT07173127","phase":"NA","title":"The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters","status":"RECRUITING","sponsor":"University Hospital, Geneva","startDate":"2025-09-30","conditions":"Uterine Fibroid","enrollment":30},{"nctId":"NCT01996046","phase":"","title":"FDG PET/CT in Breast Cancer Bone Mets","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2013-09","conditions":"Estrogen Receptor Positive Breast Cancer, Bone Metastases","enrollment":75},{"nctId":"NCT07015138","phase":"NA","title":"Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-06-01","conditions":"Prostate Cancer, Oligometastatic Prostate Cancer","enrollment":390},{"nctId":"NCT03170960","phase":"PHASE1","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2017-09-05","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":914},{"nctId":"NCT07126093","phase":"NA","title":"High-intensity Focused Ultrasound Combined With Novel Hormone Therapy in Advanced Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-10-01","conditions":"Prostate Cancer","enrollment":134},{"nctId":"NCT07104643","phase":"PHASE1, PHASE2","title":"Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）","status":"NOT_YET_RECRUITING","sponsor":"TYK Medicines, Inc","startDate":"2025-08","conditions":"mCRPC","enrollment":48},{"nctId":"NCT07104617","phase":"PHASE1, PHASE2","title":"Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）","status":"NOT_YET_RECRUITING","sponsor":"TYK Medicines, Inc","startDate":"2025-08","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC)","enrollment":48},{"nctId":"NCT07034820","phase":"NA","title":"War-Drill Model Guided Treatment of Hemorrhoids With Nimsai Herbal (NAJ)","status":"COMPLETED","sponsor":"Nimsai Academia","startDate":"2021-10-10","conditions":"Hemorrhoids, Hemorrhoidal Disease","enrollment":300},{"nctId":"NCT06610825","phase":"PHASE2","title":"Castrate Resistant Prostate Cancer Enhertu Therapy","status":"RECRUITING","sponsor":"Washington D.C. Veterans Affairs Medical Center","startDate":"2025-03-05","conditions":"Prostate Cancer Metastatic, Prostate Cancer, CRPC","enrollment":60},{"nctId":"NCT01722851","phase":"","title":"Circulating miRNAs.","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2011-05","conditions":"Breast Cancer, Newly Diagnosed Breast Cancer, Recurrent Breast Cancer","enrollment":255},{"nctId":"NCT04115007","phase":"PHASE3","title":"Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-23","conditions":"Oligometastatic Hormone Sensitive Prostate Cancer","enrollment":550},{"nctId":"NCT06151418","phase":"","title":"A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-11-22","conditions":"Prostatic Neoplasms","enrollment":2313},{"nctId":"NCT04179149","phase":"NA","title":"Enriched Environments in Endometriosis","status":"COMPLETED","sponsor":"Ponce Medical School Foundation, Inc.","startDate":"2019-09-13","conditions":"Endometriosis-related Pain, Endometriosis, Pelvic Pain","enrollment":56},{"nctId":"NCT06500741","phase":"","title":"Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2024-11-22","conditions":"Prostate Cancer","enrollment":374},{"nctId":"NCT06702995","phase":"PHASE1, PHASE2","title":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Evopoint Biosciences Inc.","startDate":"2023-04-19","conditions":"Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)","enrollment":307},{"nctId":"NCT03523351","phase":"PHASE1, PHASE2","title":"Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-05-01","conditions":"Metastatic Solid Tumors of Metastatic Disease","enrollment":78},{"nctId":"NCT06915714","phase":"","title":"The Prognostic Value of PET/CT for Tumor Progression in Patients With Metastatic Hormone-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2024-06-02","conditions":"Prostate Cancer Metastatic Disease, PET / CT","enrollment":45},{"nctId":"NCT06905210","phase":"PHASE3","title":"Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-03","conditions":"Acne Vulgaris, Acne Vulgaris on the Face","enrollment":526},{"nctId":"NCT04049747","phase":"NA","title":"Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2019-12-11","conditions":"Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Adenocarcinoma","enrollment":100},{"nctId":"NCT06865755","phase":"NA","title":"Collaborative Research: Multiscale Modeling and Intervention for Improving Long-Term Medication","status":"NOT_YET_RECRUITING","sponsor":"San Diego State University","startDate":"2025-03","conditions":"Breast Cancer Survivor, Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":15},{"nctId":"NCT06446401","phase":"","title":"The Case of \"Triple\" Versus \"Double\" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2024-10-20","conditions":"Prostate Cancer","enrollment":1400},{"nctId":"NCT04022616","phase":"","title":"Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2010-06-04","conditions":"Breast Cancer","enrollment":99},{"nctId":"NCT04070209","phase":"PHASE2","title":"Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)","status":"RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2020-10-19","conditions":"Metastatic Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":66},{"nctId":"NCT02685397","phase":"PHASE2, PHASE3","title":"Management of Castration-Resistant Prostate Cancer with Oligometastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2016-10","conditions":"Castration-resistant Prostate Cancer Patients with Oligometastases","enrollment":102},{"nctId":"NCT02366494","phase":"","title":"Micro RNAs to Predict Response to Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2015-04-29","conditions":"Prostate Cancer","enrollment":42},{"nctId":"NCT03751800","phase":"","title":"A Study Run At Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also Be Used to Assess Changes of Severity of HMB in Women with HMB Who Are Treated During 12 Months with a Chronic Hormonal Treatment","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-12-12","conditions":"Menorrhagia","enrollment":422},{"nctId":"NCT04066283","phase":"","title":"Effects of Aging and Gender-Affirming Hormone Therapy on Vascular Endothelial Function and Metabolic Profiles in Transgender Women","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2019-04-17","conditions":"Transgender, Gender Identity, Vascular Stiffness","enrollment":29},{"nctId":"NCT04237467","phase":"","title":"Effects of Aging and Gender-Affirming Hormone Therapy on Vascular Endothelial Function and Metabolic Profiles in Transgender Men","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-01-29","conditions":"Transgender, Gender Identity, Vascular Stiffness","enrollment":16},{"nctId":"NCT04498767","phase":"NA","title":"Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2021-06-10","conditions":"Gynecologic Cancer, Skin Cancer, Head and Neck Cancer","enrollment":200},{"nctId":"NCT06537765","phase":"NA","title":"Combined Effect of Therapeutic Ultrasound and Trans Cutaneous Electrical Nerve Stimulation on Endometriosis","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2024-08-10","conditions":"Endometriosis","enrollment":45},{"nctId":"NCT06505278","phase":"PHASE2","title":"The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08","conditions":"Prostate Cancer","enrollment":70},{"nctId":"NCT06455956","phase":"","title":"Use of miRNAs in Growth Hormone Deficiency (GHD)","status":"RECRUITING","sponsor":"University of Parma","startDate":"2023-04-13","conditions":"Growth Hormone Deficiency","enrollment":400},{"nctId":"NCT06405243","phase":"PHASE3","title":"Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients","status":"NOT_YET_RECRUITING","sponsor":"Beni-Suef University","startDate":"2024-06-30","conditions":"Polycystic Ovary Syndrome","enrollment":100},{"nctId":"NCT06387238","phase":"NA","title":"Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2024-05-01","conditions":"Prostate Adenocarcinoma","enrollment":150},{"nctId":"NCT02933801","phase":"PHASE2","title":"ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2017-03-31","conditions":"Prostate Cancer Metastatic, Prostate Cancer","enrollment":92},{"nctId":"NCT05539300","phase":"NA","title":"PSMA Response in Metastasized Hormone Sensitive Prostate Cancer - Enzalutamide","status":"UNKNOWN","sponsor":"UMC Utrecht","startDate":"2023-03-01","conditions":"Prostate Cancer","enrollment":150},{"nctId":"NCT05161728","phase":"NA","title":"PSMA Response in Metastasized Hormone Sensitive Prostate Cancer","status":"UNKNOWN","sponsor":"Roderick van den Bergh","startDate":"2021-10-19","conditions":"Prostate Cancer","enrollment":150},{"nctId":"NCT03949270","phase":"NA","title":"Text Messaging in Patients on Adjuvant Endocrine Therapy for Breast Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-07-22","conditions":"Breast Cancer, Adherence, Medication, Side Effect","enrollment":400},{"nctId":"NCT02284581","phase":"","title":"Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments","status":"UNKNOWN","sponsor":"Consorzio Oncotech","startDate":"2015-11","conditions":"Metastatic Breast Cancer","enrollment":10000},{"nctId":"NCT02987543","phase":"PHASE3","title":"Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-02-06","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":387},{"nctId":"NCT06031753","phase":"NA","title":"Effects of Intermittent Fasting on Polycystic Ovary Syndrome (PCOS) Compared to Standard Treatment","status":"COMPLETED","sponsor":"Instituto Superior de Investigación en Estética Médica, Nutrición y Anti-Envejecimiento","startDate":"2021-06-03","conditions":"Polycystic Ovary Syndrome, Insulin Resistance","enrollment":16},{"nctId":"NCT05324020","phase":"NA","title":"eHealth Intervention for Medication Adherence in Breast Cancer Survivors","status":"COMPLETED","sponsor":"Luxembourg Institute of Health","startDate":"2021-10-04","conditions":"Breast Cancer","enrollment":3},{"nctId":"NCT05437679","phase":"","title":"Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System","status":"TERMINATED","sponsor":"Angle plc","startDate":"2022-07-05","conditions":"High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer","enrollment":9},{"nctId":"NCT05955209","phase":"PHASE2","title":"Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-08-01","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":40},{"nctId":"NCT04676607","phase":"PHASE2","title":"SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2020-12-17","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":6},{"nctId":"NCT04930055","phase":"","title":"Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)","status":"TERMINATED","sponsor":"Indiana University","startDate":"2021-06-30","conditions":"Cancer","enrollment":2206},{"nctId":"NCT05780567","phase":"PHASE3","title":"Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-03-30","conditions":"Breast Cancer","enrollment":1946},{"nctId":"NCT03772353","phase":"PHASE1, PHASE2","title":"Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-05-12","conditions":"Breast Cancer","enrollment":59},{"nctId":"NCT03038594","phase":"PHASE2, PHASE3","title":"Growth Hormone Therapy for Muscle Regeneration in Severely Burned Patients","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2015-11-01","conditions":"Burns, Growth Hormone Treatment","enrollment":13},{"nctId":"NCT02907372","phase":"NA","title":"Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Centre Francois Baclesse","startDate":"2016-11","conditions":"Metastatic Castration-resistant Prostate Cancer (CRPCa)","enrollment":163},{"nctId":"NCT01343459","phase":"NA","title":"Intra-Operative Electron Boost and Hypofractionated Whole-Breast Irradiation During Breast-conserving Treatment (BCT)","status":"COMPLETED","sponsor":"Paracelsus Medical University","startDate":"2011-01","conditions":"Local Neoplasm Recurrence, Toxicity","enrollment":1464},{"nctId":"NCT03236545","phase":"NA","title":"Menopause Effects on Vascular Function","status":"COMPLETED","sponsor":"University of Delaware","startDate":"2016-07-01","conditions":"Cardiovascular Risk Factor","enrollment":48},{"nctId":"NCT03980093","phase":"NA","title":"The REACH Study: A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors","status":"COMPLETED","sponsor":"University of Colorado, Boulder","startDate":"2019-04-01","conditions":"Breast Cancer","enrollment":88},{"nctId":"NCT05415930","phase":"","title":"Evaluation of an Adaptative, Multidisciplinary, Reach-out Program, Facilitating Pre Exposition HIV Prophylaxis (PrEP) Prescription and Retention in Care, in a Group of Trans Womens (TW) at High Risk of HIV Infection.","status":"UNKNOWN","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2022-07-01","conditions":"Transgenderism","enrollment":100},{"nctId":"NCT03857893","phase":"NA","title":"New Non-Hormonal Treatment by Radiofrequency for Vulvo-Vaginal Atrophy","status":"TERMINATED","sponsor":"Serge Rozenberg","startDate":"2019-03-01","conditions":"Vulvo-vaginal Atrophy, Genitourinary Syndrome of Menopause","enrollment":53},{"nctId":"NCT03896984","phase":"","title":"Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-03-18","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC)","enrollment":346},{"nctId":"NCT05026073","phase":"","title":"Vibrational Spectroscopy for Endometrial Cancer Diagnosis","status":"UNKNOWN","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2020-01-19","conditions":"Endometrial Cancer, Endometrial Hyperplasia","enrollment":150},{"nctId":"NCT01201863","phase":"PHASE4","title":"Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy","status":"COMPLETED","sponsor":"Craig Hospital","startDate":"2010-09","conditions":"Endocrine Dysfunction, Trauma, Brain Injury","enrollment":46},{"nctId":"NCT04932070","phase":"NA","title":"Berberine and Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Azienda di Servizi alla Persona di Pavia","startDate":"2020-09-05","conditions":"Polycystic Ovary Syndrome, Berberine","enrollment":12},{"nctId":"NCT00290745","phase":"PHASE1, PHASE2","title":"Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2002-02-19","conditions":"Breast Cancer","enrollment":79},{"nctId":"NCT04095390","phase":"PHASE2","title":"A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer","status":"UNKNOWN","sponsor":"Jinming Yu","startDate":"2019-09-30","conditions":"Metastatic Breast Cancer, HER2-positive Breast Cancer","enrollment":60},{"nctId":"NCT02269982","phase":"","title":"Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY","status":"COMPLETED","sponsor":"Duke University","startDate":"2015-05-14","conditions":"Prostate Cancer","enrollment":120},{"nctId":"NCT03960593","phase":"","title":"Cohort of Patients Over 70 Years of Age With Cancer and / or Hematological Malignancy","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2018-11-06","conditions":"Cancer and / or Hematological Malignancy","enrollment":500},{"nctId":"NCT02053311","phase":"PHASE3","title":"Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents","status":"WITHDRAWN","sponsor":"Swiss Cancer Institute","startDate":"2014-08-19","conditions":"Prostate Cancer","enrollment":0},{"nctId":"NCT02622087","phase":"NA","title":"The Impact of Sex Hormones on One-session Treatment for Spider Phobia in Women","status":"COMPLETED","sponsor":"The University of New South Wales","startDate":"2015-11","conditions":"Phobia, Specific","enrollment":90},{"nctId":"NCT03091023","phase":"NA","title":"Quantitative Identification of Implantation Receptivity by Single Cell Transcriptome Analysis","status":"UNKNOWN","sponsor":"Igenomix","startDate":"2016-03","conditions":"Endometrial Receptivity Diagnosis","enrollment":70},{"nctId":"NCT01701050","phase":"","title":"Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index","status":"COMPLETED","sponsor":"Janssen Diagnostics, LLC","startDate":"2013-04-01","conditions":"Metastatic Breast Cancer","enrollment":121},{"nctId":"NCT00184795","phase":"PHASE3","title":"Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-05-28","conditions":"Menopause, Menopausal Vasomotor Symptoms","enrollment":576},{"nctId":"NCT01419197","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Breast Cancer","enrollment":602}],"_emaApprovals":[{"date":"","name":"Novel hormonal therapy","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL2108078","moleculeType":"Protein","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2108078"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":74,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":5,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"200000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":2,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:53:45.983742+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}